Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has disclosed new compounds acting as lipid-lowering agents and gluconeogenesis inhibitors potentially useful for the treatment of metabolic diseases.

Researchers from the Centre National de la Recherche Scientifique, the Institut National de la Santé et de la Recherche Médicale, Nanyang Technological University and the University of Montpellier have patented new Mycobacterium sp. ATP synthase (F0F1 ATPase) inhibitors potentially useful for the treatment of nontuberculous mycobacterial infections.

Wuhan Createrna Science and Technology Co. Ltd. has reported new complement factor D (CFD) inhibitors potentially useful for the treatment of cardiovascular, immunological, eye, genitourinary, renal, respiratory, neurological disorders and hematological diseases.

Nutshell Therapeutics Inc. has synthesized new nitrogen-containing heteroaryl compounds acting as Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors potentially useful for the treatment of cancer.

Novartis AG has reported new drug conjugates comprising drugs targeting fibroblast activation protein α (FAP) covalently linked to a radiolabeled chelating agent through a linker potentially useful for the treatment and/or diagnosis of cancer.

Prelude Therapeutics Inc. has identified new tyrosine-protein kinase JAK2 inhibitors potentially useful for the treatment of leukemia, polycythemia vera, myelofibrosis, essential thrombocythemia and graft-vs.-host disease.

Shenzhen Linggene Biotechnology Co. Ltd. has synthesized new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding agent coupled to a UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase (OGT)-targeting moiety acting as OGT degradation inducers.

Vastpro (Shanghai) Pharmaceutical Technology Development Co. Ltd. has patented new voltage-gated sodium channel blockers potentially useful for the treatment of pain.

Guangzhou Respiratory Medicine Engineering Technology Co. Ltd. has disclosed new cathepsin C (dipeptidyl peptidase I) and neutrophil elastase (ELANE; leukocyte elastase) inhibitors potentially useful for the treatment of asthma, diabetes, psoriasis, nasal polyps, cystic fibrosis and more.